PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, providing a therapeutic alternative for people suffering from end-stage heart failure, today announces that it has obtained approval to resume the first-in-man trial with its bioprosthetic heart.
Help employers find you! Check out all the jobs and post your resume.
